Skip to content

13F-HR filed by Indaba Capital Management, L.P.

Indaba Capital Management, L.P. filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 10 holding rows worth $207,547,740.

Accession
0001011438-25-000175
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 10 entries on the cover page, a total value of $207,547,740 stated on the cover page (in dollars after the unit check, H1), rows summing to $207,547,740 with VALUE read as dollars as filed, 13F file number 028-16058. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Blue Owl Capital Corp III69122G102COM SHS2,793,366$40,280,338dollars as filed
BANDWIDTH INC05988JAD5NOTE 0.500% 4/040,250,000$32,167,800dollars as filedprincipal
ON24 INC68339B104COM4,240,256$27,392,054dollars as filed
REVANCE THERAPEUTICS INC761330AB5BOND25,000,000$24,030,000dollars as filedprincipal
SUMMIT HOTEL PPTYS866082AA8NOTE 1.500% 2/122,664,000$21,965,949dollars as filedprincipal
EQUITY COMMONWEALTH294628102COM SH BEN INT9,550,000$16,903,500dollars as filed
IRONWOOD PHARMACEUTICALS INC46333XAH1NOTE 1.500% 6/114,000,000$13,035,400dollars as filedprincipal
TRAVERE THERAPEUTICS INC761299AB2NOTE 2.500% 9/113,000,000$12,829,700dollars as filedprincipal
ACCELERATE DIAGNOSTICS INC00430HAC6NOTE 5.000%12/124,685,998$12,342,999dollars as filedprincipal
ESPERION THERAPEUTICS INC NEW COM29664W105Stock3,000,000$6,600,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001011438-25-000175this filing2025-02-14acceptance time not in the bulk data set